Anlotinib verlengd totale overleving bij NSCLC

Bronnen:

1. Han B, Li K, Wang Q et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer. The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online August 9, 2018. doi:10.1001/jamaoncol.2018.3039